TNF-α inhibitor tanfanercept (HBM9036) improves signs and symptoms of dry eye in a phase 2 trial in the controlled adverse environment in China

PURPOSE: This study evaluated the clinical safety and efficacy of tanfanercept (HBM9036) ophthalmic solution as a novel treatment for dry eye disease (DED) in a controlled adverse environment (CAE) study conducted in China. METHODS: In a single-center, double-masked, randomized, placebo-controlled s...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Yanling, Wang, Shuang, Cong, Lin, Zhang, Ting, Cheng, Jun, Yang, Nannan, Qu, Xiaohong, Li, Dongfang, Zhou, Xueying, Wang, Holly, Lee, Michael, Wang, Meng, Chen, Stephen, Ousler, George W., Chen, Xiaoxiang, Xie, Lixin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2022
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314282/
https://www.ncbi.nlm.nih.gov/pubmed/35192105
http://dx.doi.org/10.1007/s10792-022-02245-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314282/
https://www.ncbi.nlm.nih.gov/pubmed/35192105
http://dx.doi.org/10.1007/s10792-022-02245-1

Ejemplares similares